# US 2019/0315814 A1 · Lantibiotic variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315814 A1
- Document ID: US20190315814A1
- Status: Published application
- Kind: A1
- Application number: 16/316,328
- Filed: 2017-07-14
- Published: 2019-10-17
- Earliest claimed: 2016-07-15
- Applicants: Intrexon Corporation
- Inventors: Martin HANDFIELD; Johan Anthony KERS; Sheela MULEY; Melissa MAYO; Jeffrey COLBECK; Robert Eryl SHARP; Albert G. FOSMOE, II; Anthony W. DEFUSCO
- Web page: https://patentgrep.com/patent/US20190315814A1

## CPC

- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A01N 63/50: Isolated enzymes; Isolated proteins (peptides A01N37/46)
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0058: {Chewing gums (non-medicinal aspects, preparing chewing gum A23G4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q11/00)}
- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 31/04: Antibacterial agents
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- C07K 5/02: containing at least one abnormal peptide link
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The disclosure relates to lantibiotic structural variants that have improved antimicrobial properties when compared to wild-type lantibiotics, and uses thereof. Embodiments include non-naturally occurring lantibiotics.

## Claims

### Claim 1

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising a mutation including:
a. arginine at position 13 changed to asparagine (R13N);
b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y);
c. asparagine at position 18 changed to alanine (N18A);
d. tyrosine at position 20 changed to phenylalanine (Y20F); or
e. combinations thereof.

### Claim 2

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations, wherein one mutation includes:
a. arginine at position 13 changed to asparagine (R13N);
b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y);
c. asparagine at position 18 changed to alanine (N18A);
d. tyrosine at position 20 changed to phenylalanine (Y20F); or
e. combinations thereof.

### Claim 3 (depends on 2)

The non-naturally occurring lantibiotic of claim 2, wherein one mutation is arginine at position 13 changed to asparagine (R13N).

### Claim 4 (depends on 2, 3)

The non-naturally occurring lantibiotic of claim 2 or 3, wherein one mutation is phenylalanine at position 1 changed to valine (F1V).

### Claim 5

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations, wherein one mutation includes:
a. phenylalanine at position 1 changed to valine (F1V);
b. phenylalanine at position 1 changed to alanine (F1A);
c. phenylalanine at position 1 changed to isoleucine (F1I);
d. phenylalanine at position 1 changed to leucine (F1L);
e. phenylalanine at position 1 changed to threonine (F1T); or
f. phenylalanine at position 1 changed to tyrosine (F1Y).

### Claim 6 (depends on 5)

The non-naturally occurring lantibiotic of claim 5, wherein one mutation is phenylalanine at position 1 changed to valine (F1V).

### Claim 7 (depends on 5, 6)

The non-naturally occurring lantibiotic of claim 5 or 6, wherein one mutation is arginine at position 13 changed to asparagine (R13N).

### Claim 8

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations including:
a. phenylalanine at position 1 changed to alanine in combination with arginine at position 13 changed to:
i. alanine (F1A R13A),
ii. valine (F1A R13V),
iii. asparagine (F1A R13N), or
iv. serine(F1A R13S);
b. phenylalanine at position 1 changed to glycine in combination with arginine at position 13 changed to:
i. glycine (F1G R13G);
c. phenylalanine a position 1 changed to histidine in combination with arginine at position 13 changed to:
i. asparagine (F1H R13N);
d. phenylalanine at position 1 changed to isoleucine in combination with arginine at position 13 changed to:
i. alanine (F1I R13A),
ii. glycine (F1I R13G),
iii. isoleucine (F1I R13I),
iv. asparagine (F1I R13N),
v. proline (F1I R13P),
vi. glutamine (F1I R13Q),
vii. glutamic acid (F1I R13S),
viii. serine (F1R13V), or
ix. valine (F1I R13E);
e. phenylalanine at position 1 changed to leucine in combination with arginine at position 13 changed to:
i. alanine (F1L R13A),
ii. aspartic acid (F1L R13D),
iii. glycine (F1L R13G),
iv. asparagine (F1L R13N),
v. proline (F1L R13P), or
vi. glutamine (F1L R13Q);
f. phenylalanine at position 1 changed to threonine in combination with arginine at position 13 changed to:
i. alanine (F1T R13A),
ii. asparagine (F1T R13N), or
iii. valine (F1T R13V);
g. phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to:
i. alanine (F1V R13A),
ii. asparagine (F1V R13N),
iii. glutamine (F1V R13Q),
iv. aspartic acid (F1V R13D),
v. valine (F1V R13V), or
vi. proline (F1V R13P); or
h. phenylalanine at position 1 changed to tyrosine in combination with arginine at position 13 changed to:
i. aspartic acid (F1Y R13D), or
ii. glycine (F1Y R13G).

### Claim 9 (depends on 8)

The non-naturally occurring lantibiotic of claim 8, comprising two mutations including phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to:
i. alanine (F1V R13A),
ii. asparagine (F1V R13N),
iii. glutamine (F1V R13Q),
iv. aspartic acid (F1V R13D),
v. valine (F1V R13V), or
vi. proline (F1V R13P).

### Claim 10 (depends on 9)

The non-naturally occurring lantibiotic of claim 9, wherein the two mutations consist of phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to asparagine (F1V R13N).

### Claim 11

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising three mutations including:
a. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with glycine at position 15 changed to alanine (F1I R13A G15A);
b. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with glycine at position 15 changed to alanine (F1I R13D G15A);
c. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to isoleucine, in combination with arginine at position 13 changed to alanine (F1I W4I R13A);
d. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to aspartic acid (F1I W4M R13D);
e. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to asparagine (F1I W4M R13N);
f. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with arginine at position 13 changed to alanine (F1I K2A R13A);
g. phenylalanine at position 1 changed to isoleucine, in combination with leucine at position 6 changed to valine, in combination with arginine at position 13 changed to alanine (F1I L6V R13A);
h. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13A Y20F);
i. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13D Y20F);
j. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13N Y20F);
k. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13N Y20F);
l. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13A Y20F); or
m. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13D Y20F).

### Claim 12

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising mutations wherein:
a. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to alanine (F1I K2A W4K R13A); or
b. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to aspartic acid (F1I K2A W4K R13D).

### Claim 13

A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising mutations wherein phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I K2A W4K R13A Y20F).

### Claim 14

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising a mutation including:
a. arginine at position 13 changed to asparagine (R13N);
b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y);
c. asparagine at position 18 changed to alanine (N18A);
d. tyrosine at position 20 changed to phenylalanine (Y20F); or
e. combinations thereof.

### Claim 15

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising two mutations, wherein one mutation includes:
a. arginine at position 13 changed to asparagine (R13N);
b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y);
c. asparagine at position 18 changed to alanine (N18A);
d. tyrosine at position 20 changed to phenylalanine (Y20F); or
e. combinations thereof.

### Claim 16 (depends on 15)

The non-naturally occurring, post-translationally modified lantibiotic of claim 15, wherein one mutation is arginine at position 13 changed to asparagine (R13N).

### Claim 17 (depends on 15, 16)

The non-naturally occurring, post-translationally modified lantibiotic of claim 15 or 16, wherein one mutation is phenylalanine at position 1 changed to valine (F1V).

### Claim 18

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising two mutations, wherein one mutation includes:
a. phenylalanine at position 1 changed to valine (F V);
b. phenylalanine at position 1 changed to alanine (F1A);
c. phenylalanine at position 1 changed to isoleucine (F1I);
d. phenylalanine at position 1 changed to leucine (F1L);
e. phenylalanine at position 1 changed to threonine (F1T); or
f. phenylalanine at position 1 changed to tyrosine (F1Y).

### Claim 19 (depends on 18)

The non-naturally occurring, post-translationally modified lantibiotic of claim 18, wherein one mutation is phenylalanine at position 1 changed to valine (F1V).

### Claim 20 (depends on 18, 19)

The non-naturally occurring, post-translationally modified lantibiotic of claim 18 or 19, wherein one mutation is arginine at position 13 changed to asparagine (R13N).

### Claim 21

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising two mutations including:
a. phenylalanine at position 1 changed to alanine in combination with arginine at position 13 changed to:
i. alanine (F1A R13A),
ii. valine (F1A R13V),
iii. asparagine (F1A R13N), or
iv. serine(F1A R13S);
b. phenylalanine at position 1 changed to glycine in combination with arginine at position 13 changed to:
i. glycine (F1G R13G);
c. phenylalanine a position 1 changed to histidine in combination with arginine at position 13 changed to:
i. asparagine (F1H R13N);
d. phenylalanine at position 1 changed to isoleucine in combination with arginine at position 13 changed to:
i. alanine (F1I R13A),
ii. glycine (F1I R13G),
iii. isoleucine (F1I R13I),
iv. asparagine (F1I R13N),
v. proline (F1I R13P),
vi. glutamine (F1I R13Q),
vii. glutamic acid (F1I R13S),
viii. serine (F1I R13V), or
ix. valine (F1I R13E);
e. phenylalanine at position 1 changed to leucine in combination with arginine at position 13 changed to:
i. alanine (F1L R13A),
ii. aspartic acid (F1L R13D),
iii. glycine (F1L R13G),
iv. asparagine (F1L R13N),
v. proline (F1L R13P), or
vi. glutamine (F1L R13Q);
f. phenylalanine at position 1 changed to threonine in combination with arginine at position 13 changed to:
i. alanine (F1T R13A),
ii. asparagine (F1T R13N), or
iii. valine (F1T R13V);
g. phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to:
i. alanine (F1V R13A),
ii. asparagine (F1V R13N),
iii. glutamine (F1V R13Q),
iv. aspartic acid (F1V R13D),
v. valine (F1V R13V), or
vi. proline (F1V R13P); or
h. phenylalanine at position 1 changed to tyrosine in combination with arginine at position 13 changed to:
i. aspartic acid (F1Y R13D), or
ii. glycine (F1Y R13G).

### Claim 22 (depends on 21)

The non-naturally occurring, post-translationally modified lantibiotic of claim 21, comprising two mutations including phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to:
i. alanine (F1V R13A),
ii. asparagine (F1V R13N),
iii. glutamine (F1V R13Q),
iv. aspartic acid (F1V R13D),
v. valine (F1V R13V), or
vi. proline (F1V R13P).

### Claim 23 (depends on 22)

The non-naturally occurring, post-translationally modified lantibiotic of claim 22, wherein the two mutations consist of phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to asparagine (F1V R13N) (SEQ ID NO: 550).

### Claim 24

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising three mutations including:
a. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with glycine at position 15 changed to alanine (F1I R13A G15A);
b. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with glycine at position 15 changed to alanine (F1I R13D G15A);
c. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to isoleucine, in combination with arginine at position 13 changed to alanine (F1I W4I R13A);
d. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to aspartic acid (F1I W4M R13D);
e. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to asparagine (F1I W4M R13N);
f. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with arginine at position 13 changed to alanine (F1I K2A R13A);
g. phenylalanine at position 1 changed to isoleucine, in combination with leucine at position 6 changed to valine, in combination with arginine at position 13 changed to alanine (F1I L6V R13A);
h. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13A Y20F);
i. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13D Y20F);
j. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13N Y20F);
k. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13N Y20F);
l. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13A Y20F); or
m. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13D Y20F).

### Claim 25

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising mutations wherein:
a. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to alanine (F1I K2A W4K R13A); or
b. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to aspartic acid (F1I K2A W4K R13D).

### Claim 26

A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO: 1156) and further comprising mutations wherein phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I K2A W4K R13A Y20F).

### Claim 27

A non-naturally occurring lantibiotic comprising a single amino acid mutation of MU1140, the lantibiotic having an amino acid sequence encoded by of any one of SEQ ID NOS:2 to 431.

### Claim 28

A non-naturally occurring lantibiotic comprising multisite amino acid mutations of MU1140, the lantibiotic being a variant as described in FIG. 7.

### Claim 29

A non-naturally occurring lantibiotic comprising any variant as described in FIG. 8: Group 1, Group 2 or Group 3.

### Claim 30

A non-naturally occurring lantibiotic comprising any variant as described in FIG. 8: Group 1.

### Claim 31

A non-naturally occurring lantibiotic comprising a single amino acid mutation of MU1140 as described in FIG. 6.

### Claim 32

A non-naturally occurring lantibiotic comprising an amino acid sequence of SEQ ID NO. 550.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The non-naturally occurring lantibiotic of any one of claim 27 to 32, wherein the lantibiotic is post-translationally modified.

### Claim 34 (depends on 33)

The non-naturally occurring lantibiotic of claim 33, wherein the post-translation modification comprises Dha at position 5.

### Claim 35 (depends on 33, 34)

The non-naturally occurring lantibiotic of claim 33 or claim 34, wherein the post-translation modification comprises Abu at position 8.

### Claim 36 (depends on 33, 35)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 35, wherein the post-translation modification comprises Dhb at position 14.

### Claim 37 (depends on 33, 36)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 36, wherein the post-translation modification comprises Dha at position 5, Abu at position 8, and Dhb at position 14.

### Claim 38 (depends on 33, 37)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 37, wherein the post-translation modification comprises a ring formed by lanthionine (Ala-S-Ala) residues between (Ala3-S-Ala7) as described in FIG. 1 (Ring A).

### Claim 39 (depends on 33, 38)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 38, wherein the post-translation modification comprises a methyl-lanthionine residue (Abu-S-Ala) forming a ring, Ring B, comprising the alpha-aminobutyrate residue in position 8 and the Ala in position 11 (Abu8-S-Ala11) as described in FIG. 1.

### Claim 40 (depends on 33, 39)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 39, wherein the post-translation modification comprises a ring formed by lanthionine (Ala-S-Ala) residues between (Ala16-S-Ala21) as described in FIG. 1 (Ring C).

### Claim 41 (depends on 33, 40)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 40, wherein the post-translation modification comprises Ala in position 19 linked to an aminovinyl group by a thioether linkage (Ala19-S—CH═CH—NH—), Ring D, as described in FIG. 1.

### Claim 42 (depends on 33, 41)

The non-naturally occurring lantibiotic of any one of claim 33 to claim 41, wherein the post-translation modification comprises Ring A, B, C and D.

### Claim 43 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The non-naturally occurring lantiobiotic of any one of claims 33 to 42, wherein the post-translationally modified MU1140 variant comprises Ring A, Ring B, Ring C and Ring D, wherein:
a. two of these rings are formed by lanthionine (Ala-S-Ala) residues, including one in Ring A (Ala3-S-Ala7) and one in Ring C (Ala16-S-Ala21);
b. a methyl-lanthionine residue (Abu-S-Ala) forms Ring B comprising the alpha-aminobutyrate residue in position 8 and the Ala in position 11 (Abu8-S-Ala11); and
c. the fourth ring, D, is comprised of the Ala in position 19 linked to an aminovinyl group by a thioether linkage (Ala19-S—CH═CH—NH—).
and wherein amino acid at position 5 is modified to Dha, the amino acid at position 8 is modified to Abu, and the amino acid at position 14 is modified to Dhb.

### Claim 44

An isolated lantibiotic variant, wherein the isolated lantibiotic variant is produced in a host cell by expressing a polypeptide from a polynucleotide encoding a lantibiotic variant of FIG. 5 or FIG. 7, and wherein the expressed polypeptide is post-translationally modified in the host cell.

### Claim 45 (depends on 44)

The isolated lantibiotic variant of claim 44, wherein the host cell is S. mutans.

### Claim 46

A post-translationally modified, non-naturally occurring lantibiotic comprising an amino acid sequence of SEQ ID NO. 1157.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

An antimicrobial composition comprising a non-naturally occurring lantibiotic of any one of claims 1 to 26 or 33 to 46 and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, other diluent or excipient.

### Claim 48 (depends on 47)

The antimicrobial composition of claim 47, further comprising an antifungal agent, an additional antimicrobial agent, a membrane disrupting agent, or a combination thereof.

### Claim 49 (depends on 48)

The antimicrobial composition of claim 48, wherein the additional antimicrobial agent has Gram negative bacteriostatic or bacteriocidal activity and the membrane disrupting agent renders Gram negative bacteria susceptible to the variant lantibiotic.

### Claim 50 (depends on 47, 48, 49)

The antimicrobial composition of any one of claims 47 to 49, wherein the non-naturally occurring lantibiotics is present in the composition at about 0.001, 0.01, 0.1, 1, 5, 10, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 mg/kg or mg/L.

### Claim 51 (depends on 47, 48, 49, 50)

A method of reducing reproduction of bacteria or reducing numbers of bacteria present in or on a subject, comprising administering to the subject a therapeutically effective amount of the antimicrobial composition of any one of claims 47 to 50.

### Claim 52 (depends on 51)

The method of claim 51, wherein the subject is a human.

### Claim 53 (depends on 47, 52)

The method of claim 47 or 52, wherein the composition is administered orally, topically, nasally, buccally, sublingually, transmucosally, rectally, transdermally, by inhalation, by injection or intrathecally.

### Claim 54 (depends on 53)

The method of claim 53, wherein the injection is intramuscular, intravenous, intrapulmonary, intramuscular, intradermal, intraperitoneal, intrathecal, or subcutaneous injection.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A preservative comprising an effective amount of the non-naturally occurring lantibiotic of any one of claims 1 to 26 or 33 to 46 in a physiological solution at a pH of between 3 and 8.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A food, beverage, gum, or dentifrice composition comprising an amount of the non-naturally occurring lantibiotic of any one of claims 1 to 26 or 33 to 46 sufficient to reduce the reproduction of bacteria or numbers of bacteria in the composition.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method of reducing reproduction of bacteria or reducing numbers of bacteria present in or on a composition or object, comprising contacting the antimicrobial composition of any one of claims 1 to 26 or 33 to 46 with the composition or object for a period effective to reduce reproduction of bacteria or reduce numbers of bacteria in or on the composition or object.

### Claim 58 (depends on 57)

The method of claim 57, wherein the composition is a food, beverage, gum, or dentifrice.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A composition comprising a solid surface or a textile with the lantibiotic composition of any one of claims 1 to 26 or 33 to 46 or coated onto, immobilized, linked, or bound to the solid surface or textile.

### Claim 60 (depends on 47, 48, 49, 50)

A method of reducing a biofilm or biofouling condition comprising contacting the antimicrobial composition of any one of claims 47 to 50 with the biofilm or biofouling condition for a period effective to reduce reproduction of bacteria or reduce numbers of bacteria in or on the biofilm or biofouling condition.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A kit comprising the lantibiotic of any one of claims 1 to 26 or 33 to 46 and one or more applicators.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method of preventing or treating a subject diagnosed with a bacterial infection, comprising administering the non-naturally occurring lantibiotic of any one of claims 1 to 26 or 33 to 46.

### Claim 63 (depends on 62)

The method of claim 62, wherein the subject is a human.

### Claim 64 (depends on 62, 63)

The method of claim 62 or 63, wherein the subject is infected with a Gram-positive bacteria.

### Claim 65 (depends on 64)

The method of claim 64, wherein the Gram-positive bacteria is one or more of Staphylococcus epidermidis, vancomycin resistant Enterococci, vancomycin resistant Enterococcus faecalis, Enterococcus faecalis, Enterococcus faecium, Propionibacterium acnes, Streptococcus salivarius, Streptococcus sanguis, Streptococcus mitis, Streptococcus pyogenes, Lactobacillus salivarius, Listeria monocytogenes, Actinomyces israelii, Actinomyces naeslundii, Actinomyces viscosus, Bacillus anthracis, Streptococcus agalactiae, Streptococcus intermedius, Streptococcus pneumoniae, Corynebacterium diphtheria, Clostridium sporogenes Clostridium botulinum, Clostridium perfringens, Clostridium tetani, or Clostridium difficile.

### Claim 66 (depends on 65)

The method of claim 65, wherein the Gram-positive bacteria is Clostridium difficile.

### Claim 67 (depends on 62, 63)

The method of claim 62 or 63, wherein the subject is infected with a Gram-negative bacteria.

### Claim 68 (depends on 67)

The method of claim 67, wherein the Gram-negative bacteria is one or more of Acinetobacter baumanii, Bordatella pertussis, Borrelia burgdotieri, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Coxiella burnetii, Escherichia coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira interrogans, Neisseria gonorrhoeae, Neisseria meningitides, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella enteritidis, Salmonella typhi, Salmonella typhimurium, Serratia marcescens, Shigella sonnei, Treponema pallidum, Vibrio cholera, Yersinia enterocolitica, or Yersinia pestis.

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 62 to 68, wherein the non-naturally occurring lantibiotic further comprises one or more additional antimicrobial agents, membrane disrupting agents, or combinations thereof.

### Claim 70 (depends on 46)

An antimicrobial composition, comprising the non-naturally occurring lantibiotic of claim 46, and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, other diluent, excipient, or combinations thereof.

### Claim 71 (depends on 47)

The antimicrobial composition of claim 47, further comprising an antifungal agent, an additional antimicrobial agent, a membrane disrupting agent, or a combination thereof.

### Claim 72 (depends on 48)

The antimicrobial composition of claim 48, wherein the additional antimicrobial agent has Gram negative bacteriostatic or bacteriocidal activity and the membrane disrupting agent renders Gram negative bacteria susceptible to the variant lantibiotic.

### Claim 73 (depends on 70, 71, 72)

The antimicrobial composition of any one of claims 70 to 72, wherein the non-naturally occurring lantibiotic is present in the composition at about 0.001, 0.01, 0.1, 1, 5, 10, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 mg/kg or mg/L.

### Claim 74 (depends on 70, 71, 72, 73)

A method of reducing reproduction of bacteria or reducing numbers of bacteria present in or on a subject, comprising administering to the subject a therapeutically effective amount of the antimicrobial composition of any one of claims 70 to 73.

### Claim 75 (depends on 74)

The method of claim 74, wherein the subject is a human.

### Claim 76 (depends on 73, 74)

The method of claim 73 or 74, wherein the composition is administered orally, topically, nasally, buccally, sublingually, transmucosally, rectally, transdermally, by inhalation, by injection, or intrathecally.

### Claim 77 (depends on 75)

The method of claim 75, wherein the injection is intramuscular, intravenous, intrapulmonary, intramuscular, intradermal, intraperitoneal, intrathecal, or subcutaneous injection.

### Claim 78 (depends on 46)

A preservative comprising an effective amount of the non-naturally occurring lantibiotic of claim 46 in a physiological solution at a pH of between 3 and 8.

### Claim 79 (depends on 46)

A food, beverage, gum, or dentifrice composition comprising an amount of the non-naturally occurring lantibiotic of claim 46 sufficient to reduce the reproduction of bacteria or numbers of bacteria in the composition.

### Claim 80 (depends on 46)

A method of reducing reproduction of bacteria or reducing numbers of bacteria present in or on a composition or object, comprising contacting the non-naturally occurring lantibiotic of claim 46 with the composition or object for a period effective to reduce reproduction of bacteria or reduce numbers of bacteria in or on the composition or object.

### Claim 81 (depends on 80)

The method of claim 80, wherein the composition is a food, beverage, gum, or dentifrice.

### Claim 82 (depends on 46)

A composition comprising a solid surface or a textile with the non-natrually occurring lantibiotic of claim 46 or coated onto, immobilized, linked, or bound to the solid surface or textile.

### Claim 83 (depends on 46)

A method of reducing a biofilm or biofouling condition comprising contacting the non-naturally occurring lantibiotic of claim 46 with the biofilm or biofouling condition for a period effective to reduce reproduction of bacteria or reduce numbers of bacteria in or on the biofilm or biofouling condition.

### Claim 84 (depends on 46)

A kit comprising the lantibiotic of claim 46 and one or more applicators.

### Claim 85 (depends on 46)

A method of preventing or treating a subject diagnosed with a bacterial infection, comprising administering the non-naturally occurring lantibiotic of claim 46.

### Claim 86 (depends on 85)

The method of claim 85, wherein the subject is a human.

### Claim 87 (depends on 85, 86)

The method of claim 85 or 86, wherein the subject is infected with a Gram-positive bacteria.

### Claim 88 (depends on 87)

The method of claim 87, wherein the Gram-positive bacteria is one or more of Staphylococcus epidermidis, vancomycin resistant Enterococci, vancomycin resistant Enterococcus faecalis, Enterococcus faecalis, Enterococcus faecium, Propionibacterium acnes, Streptococcus salivarius, Streptococcus sanguis, Streptococcus mitis, Streptococcus pyogenes, Lactobacillus salivarius, Listeria monocytogenes, Actinomyces israelii, Actinomyces naeslundii, Actinomyces viscosus, Bacillus anthracis, Streptococcus agalactiae, Streptococcus intermedius, Streptococcus pneumoniae, Corynebacterium diphtheria, Clostridium sporogenes Clostridium botulinum, Clostridium perfringens, Clostridium tetani, or Clostridium difficile.

### Claim 89 (depends on 88)

The method of claim 88, wherein the Gram-positive bacteria is Clostridium difficile.

### Claim 90 (depends on 85, 86)

The method of claim 85 or 86, wherein the subject is infected with a Gram-negative bacteria.

### Claim 91 (depends on 90)

The method of claim 90, wherein the Gram-negative bacteria is one or more of Acinetobacter baumanii, Bordatella pertussis, Borrelia burgdotieri, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Coxiella burnetii, Escherichia coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira interrogans, Neisseria gonorrhoeae, Neisseria meningitides, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella enteritidis, Salmonella typhi, Salmonella typhimurium, Serratia marcescens, Shigella sonnei, Treponema pallidum, Vibrio cholera, Yersinia enterocolitica, or Yersinia pestis.

### Claim 92 (depends on 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 85 to 91, wherein the non-naturally occurring lantibiotic further comprises one or more additional antimicrobial agents, membrane disrupting agents, or combinations thereof.

### Claim 93

A purified polynucleotide comprising any one of SEQ ID NOs: 2-431 or encoding a variant as described in FIG. 7 or combinations thereof.

### Claim 94

A purified polynucleotide comprising any one of SEQ ID NOs: 756, 757, 758, 759, or 760.

### Claim 95

A purified polynucleotide comprising any one of SEQ ID NOs: 709, 714, 716, 735, 747, 751, 754, or 758.

### Claim 96

A purified polynucleotide comprising SEQ ID NO: 758.

### Claim 97

A purified polynucleotide comprising SEQ ID NO: 1163.

### Claim 98

A host cell comprising a polynucleotide of SEQ ID NO: 758.

### Claim 99

A host cell comprising a polynucleotide of SEQ ID NO: 1163.

### Claim 100

An isolated recombinant Streptococcus mutans strain comprising a polynucleotide of SEQ ID NO: 758.

### Claim 101

An isolated recombinant Streptococcus mutans strain comprising a polynucleotide of SEQ ID NO: 1163.

### Claim 102

A non-naturally occurring polypeptide comprising an amino acid sequence of SEQ ID NO. 1161.

### Claim 103 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

An isolated recombinant Streptococcus mutans strain comprising: (a) a mutation in a polynucleotide involved in lactic acid synthesis such that expression of lactic acid is diminished by about 80% or more as compared to a wildtype S. mutans strain; (b) a recombinant alcohol dehydrogenase polynucleotide; and (c) a recombinant polynucleotide encoding the non-naturally occurring lantibiotic of any one of claims 1 to 26 or 33 to 46
